Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Signal Transduct Target Ther · 2026 · PMC13071078 · PMID 41968137

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the final OS analysis at the time point did not reach statistical significance, sensitivity analyses adjusting for subsequent antitumor therapies demonstrated a survival benefit with deutenzalutamide over placebo (HR ~ 0.65–0.73).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.